Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906896 | 1.00 | ESR1 (0.39) | ESR1HTR2CHTR2AHTR2BSLC6A2 | |
| SCHEMBL6907948 | 0.73 | ACHE (0.43) | HTR2CHTR2AHTR2BTSHRACHE | |
| SCHEMBL6907952 | 0.73 | ACHE (0.43) | HTR2CHTR2AHTR2BTSHRACHE | |
| SCHEMBL6276896 | 0.71 | EPHX1 (0.61) | HTR2BSLC6A2TSHRSLC6A3EPHX1 | |
| SCHEMBL29657678 | 0.68 | HTR2C (0.43) | HTR2CHTR2AHTR2BSLC6A2TSHR | |
| SCHEMBL9420771 | 0.68 | HTR2C (0.43) | HTR2CHTR2AHTR2BSLC6A2TSHR | |
| SCHEMBL16795869 | 0.67 | HTR2C (0.38) | HTR2CHTR2AHTR2BTSHRACHE | |
| SCHEMBL4087274 | 0.67 | HTR2C (0.42) | HTR2CHTR2AHTR2BTSHRACHE | |
| SCHEMBL9849476 | 0.66 | TSHR (0.45) | HTR2CHTR2AHTR2BTSHRACHE | |
| SCHEMBL14012479 | 0.65 | HTR2C (0.40) | HTR2CHTR2AHTR2BTSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686483-B2 | REACTING AN OXIDIZER WITH AN OLEFIN IN PRESENCE OF KETONE | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| US-20020133031-A1 | Catalytic asymmetric epoxidation | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-09-19 | — | — | US | disclosed |
| US-6348608-B1 | ADDING OXIDIZING AGENT TO REACTION SOLUTION COMPRISING CHIRAL CYCLIC ENANTIOMERICALLY ENRICHED KETONE AND OLEFIN UNDER CONDITIONS EFFECTIVE TO GENERATE ENANTIOMERICALLY ENRICHED EPOXIDE, SEPARATING EPOXIDE FROM REACTION SOLUTION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133031-A1 | Catalytic asymmetric epoxidation | CBR1, AOX1, CBR3 | ESR1 1682/4885HTR2C 4593/4885HTR2A 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.